Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis.

ABSTRACT

Background: More and more trials have been conducted. We aimed to assess the efficacy and safety of different JAKinibs in RA. Methods: A systematic search of randomized controlled trials (RCTs) with JAKinib treatment in RA published in the Medline, Embase, and Cochrane databases up to May 2021 was performed. Results: 37 trials involving 15,174 patients were identified. Pooled analysis revealed that JAKinibs were associated with significant therapeutic improvement in RA patients as determined by ACR20 (RR = 2.03, 95% CI 1.85 to 2.28) and HAQ-DI (MD = −0.31, 95% CI −0.33 to −0.28) over placebo. Compared to placebo, JAKinib treatment was also associated with more adverse events (RR = 1.10, p < 0.001; RR = 1.29, p < 0.001; RR = 1.59, p = 0.02). Baricitinib and upadacitinib were related to more frequent adverse events (RR = 1.10; 95% CI 1.01, 1.21; RR = 1.19; 95% CI 1.11, 1.28) and infection (RR = 1.22; 95% CI 1.09, 1.37; RR = 1.38; 95% CI 1.22, 1.56), whereas only baricitinib was associated with more herpes zoster (RR = 3.15; 95% CI 1.19, 8.33). Conclusions: JAKinibs were superior to placebo for improving signs, symptoms, and health-related quality of life in RA patients at short term, whereas the overall risk of adverse events and infections were greater with baricitinib and upadacitinib, and a higher risk of herpes zoster was only associated with baricitinib. More trials are needed to investigate the long-term safety.